ScripAkeso has garnered a regulatory nod for penpulimab from the US Food and Drug Administration, making the agent the second PD-1 checkpoint inhibitor originating from a Chinese drug maker in the US marke
ScripResults from a Phase III study in China of Akeso and Summit Therapeutics’ ivonescimab in non-small cell lung cancer (NSCLC) are an encouraging sign for the PD-1/VEGF-targeting bispecific antibody’s pi
ScripThe number of drug candidates in the pipeline in 2024 rose by its lowest rate so far this decade, with the total at the turn of the year hitting 23,875. The 4.60% increase over 2024’s pipeline figure
ScripThe biopharma sector saw another setback for the once-hot anti-TIGIT class on 3 April as BeiGene said it would end a Phase III trial of its antibody candidate ociperlimab (BGB-A1217) in non-small cell